Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Eisai
Company Monitoring Page for Eisai
latest headlines for company on cafepharma
Eisai goes after head and neck cancer in Made of More campaign
Medical Marketing and Media
Mon, 06/12/23 - 11:24 pm
Tags:
Eisai
,
head and neck cancer
,
pharma marketing
FDA panel backs full approval for Eisai, Biogen Alzheimer’s drug
BioPharma Dive
Sun, 06/11/23 - 11:14 pm
Tags:
Eisai
,
Biogen
,
Leqembi
,
FDA
,
Alzheimer's disease
Pharmaceutical Giant Eisai Hit By Ransomware Incident
Infosecurity Magazine
Sun, 06/11/23 - 11:09 pm
Tags:
Eisai
,
cyberattack
,
ransomware
Eisai files Leqembi in Korea, as US prospects firm up
Pharmaphorum
Thu, 06/8/23 - 10:02 am
Tags:
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
,
South Korea
,
Asia
Ahead of key meeting, FDA appears open to full approval of Alzheimer’s drug Leqembi
BioPharma Dive
Wed, 06/7/23 - 09:53 pm
Tags:
FDA
,
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
Alzheimer’s Drug Market To Hit $13 Billion As FDA Approvals And Insurance Coverage Escalate
Forbes
Wed, 06/7/23 - 09:34 pm
Tags:
Alzheimer's disease
,
FDA
,
insurance
,
Leqembia
,
Biogen
,
Eisai
,
Eli Lilly
,
donanemab
FDA Removes Expert with Ties to Eisai, Biogen from Leqembi Adcomm
BioSpace
Tue, 06/6/23 - 10:17 am
Tags:
FDA
,
Biogen
,
Eisai
,
Alzheimer's disease
,
Leqembi
PhRMA cries foul on CMS' registry approach for Alzheimer's disease drugs
Fierce Pharma
Sun, 06/4/23 - 04:15 pm
Tags:
Biogen
,
Eisai
,
Alzheimer's disease Leqembi
,
CMS
,
PhRMA
Medicare outlines plan to expand coverage for costly new Alzheimer’s drugs
Washington Post, DC
Fri, 06/2/23 - 10:18 am
Tags:
Medicare
,
Alzheimer's disease
,
Eisai
,
Biogen
,
Leqembi
The Alzheimer's pipeline is as strong as ever. Now, we just need the patients
Fierce Biotech
Wed, 05/31/23 - 07:02 pm
Tags:
Alzheimer's disease
,
patients
,
clinical trials
,
Biogen
,
Eisai
,
Eli Lilly
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
Wed, 05/31/23 - 10:51 am
Tags:
FDA
,
Albireo Pharma
,
Aldeyra Therapeutics
,
Alvotech
,
Amneal Pharmaceuticals
,
Argenx
,
ARS Pharmaceuticals
,
AstraZeneca
,
Bayer
,
Bio-Thera Solutions
,
Biogen
,
BioMarin Pharmaceutical
,
Bristol Myers Squibb
,
Eisai
,
Eton Pharmaceuticals
,
F2G
,
Fabre-Kramer Pharmaceuticals
,
Fresenius
,
GSK
,
Intercept Pharmaceuticals
,
Ipsen
,
Ironwood Pharmaceuticals
,
Merck
,
Novaliq
,
Pfizer
,
Regeneron
,
Roche
,
Sanofi
,
Sarepta Therapeutics
,
Shionogi
,
Swedish Orphan Biovitrum
,
Takeda
,
Teva Pharmaceutica
,
UCB Pharma
Merck and Eisai tease results for renal carcinoma treatment
Clinical Trials Arena
Tue, 05/30/23 - 09:18 pm
Tags:
Merck
,
Eisai
,
ASCO 2023
,
Lenvima
,
Keytruda
,
renal cell carcinoma
Amyloid-Beta Structure Revelation Sheds Light on Leqembi’s Function
BioSpace
Wed, 05/24/23 - 06:51 pm
Tags:
Eisai
,
Biogen
,
Alzheimer's disease
,
Leqembi
,
amyloid beta
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Mon, 05/15/23 - 06:20 pm
Tags:
Biogen
,
Eisai
,
Leqembi
,
drug pricing
,
Medicare
,
Alzheimer's disease
,
JAMA
Eisai Pays up to $2B for ADC Bearing Its Halaven as Payload
BioSpace
Tue, 05/9/23 - 11:07 am
Tags:
Eisai
,
Bliss Biopharmaceutical
,
clinical trials
,
antibody-drug conjugate
,
Halaven
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Fri, 04/7/23 - 01:58 pm
Tags:
Merck
,
Keytruda
,
Eisai
,
Lenvima
,
melanoma
,
clinical trials
,
cancer
,
colorectal cancer
Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO
Fierce Pharma
Tue, 03/21/23 - 09:58 pm
Tags:
Eisai
,
Leqembi
,
FDA
,
CMS
,
Alzheimer's disease
Alzheimer's Association campaigns for broader Leqembi coverage: report
Fierce Pharma
Fri, 03/17/23 - 11:43 am
Tags:
CMS
,
Eisai
,
Biogen
,
Leqembi
,
Alzheimer's disease
VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm
Endpoints
Mon, 03/13/23 - 04:44 pm
Tags:
VHA
,
Eisai
,
Biogen
,
Leqembi
,
Aduhelm
,
Alzheimer's disease
Eisai projects $7B in sales by 2030 for new Alzheimer's drug
Endpoints
Sun, 03/12/23 - 09:40 pm
Tags:
Eisai
,
Biogen
,
Alzheimer's disease
,
Leqembi
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
a dog would most likely chase a: cat, rock, house
*
Fill in the blank.